Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenzo Falchi

Showing results (41-50 of 80) with videos related to

Pageof 8
Sort By:
Haematologica|July 10, 2009
Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter studyUmberto Vitolo, Annalisa Chiappella, Emanuele Angelucci, et al.
Haematologica|August 18, 2025
Two decades of single-institution data reveal rare long-term survivors of relapsed/refractory Burkitt lymphomaRabeya Molla, Kurt Bantilan, Ellin Berman, et al.
Annals of the American Thoracic Society|February 21, 2026
The Complementary Roles of EBUS-Guided Needle Aspiration, Mini-Forceps, and Cryobiopsy in the Investigation of Mediastinal LesionsOr Kalchiem-Dekel, Brie E Kezlarian-Sachs, Xiaoyue Ma, et al.
Leukemia & Lymphoma|November 17, 2021
Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experienceTerry K Pak, Brianne N Dixon, Michael J Buege, et al.
The Lancet. Oncology|December 26, 2017
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trialOwen A O'Connor, Jennifer K Lue, Ahmed Sawas, et al.
Haematologica|August 30, 2023
Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomesPaola Ghione, Salma Ahsanuddin, Efrat Luttwak, et al.
Bone Marrow Transplantation|November 18, 2025
Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impactMagdalena Corona, Samantha Brown, Kai Rejeski, et al.
The American Journal of Surgical Pathology|December 20, 2022
Diagnostic Discrepancies in Small-volume Biopsy for the Initial Diagnosis, Recurrence, and Transformation of Follicular Lymphoma: A Multi-Institutional Collaborative StudyAshley K Volaric, Oscar Lin, Ronald Balassanian, et al.
Blood|November 10, 2020
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 studyLorenzo Falchi, Helen Ma, Sandra Klein, et al.
Haematologica|September 5, 2024
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experienceGiulio Cassanello, Esther Drill, Alfredo Rivas-Delgado, et al.
Pageof 8

Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Haematologica|July 10, 2009
Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter studyUmberto Vitolo, Annalisa Chiappella, Emanuele Angelucci, et al.
Haematologica|August 18, 2025
Two decades of single-institution data reveal rare long-term survivors of relapsed/refractory Burkitt lymphomaRabeya Molla, Kurt Bantilan, Ellin Berman, et al.
Annals of the American Thoracic Society|February 21, 2026
The Complementary Roles of EBUS-Guided Needle Aspiration, Mini-Forceps, and Cryobiopsy in the Investigation of Mediastinal LesionsOr Kalchiem-Dekel, Brie E Kezlarian-Sachs, Xiaoyue Ma, et al.
Leukemia & Lymphoma|November 17, 2021
Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experienceTerry K Pak, Brianne N Dixon, Michael J Buege, et al.
The Lancet. Oncology|December 26, 2017
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trialOwen A O'Connor, Jennifer K Lue, Ahmed Sawas, et al.
Haematologica|August 30, 2023
Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomesPaola Ghione, Salma Ahsanuddin, Efrat Luttwak, et al.
Bone Marrow Transplantation|November 18, 2025
Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impactMagdalena Corona, Samantha Brown, Kai Rejeski, et al.
The American Journal of Surgical Pathology|December 20, 2022
Diagnostic Discrepancies in Small-volume Biopsy for the Initial Diagnosis, Recurrence, and Transformation of Follicular Lymphoma: A Multi-Institutional Collaborative StudyAshley K Volaric, Oscar Lin, Ronald Balassanian, et al.
Blood|November 10, 2020
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 studyLorenzo Falchi, Helen Ma, Sandra Klein, et al.
Haematologica|September 5, 2024
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experienceGiulio Cassanello, Esther Drill, Alfredo Rivas-Delgado, et al.
Pageof 8